Skip to main content

Recent Developments in the Pharmacological Properties of 4'-Geranyloxyferulic Acid, a Colon Cancer Chemopreventive Agent of Natural Origin

Buy Article:

$68.00 + tax (Refund Policy)

3-(4'-Geranyloxy-3'-methoxyphenyl)-2-trans propenoic acid (4'-geranyloxyferulic acid, GOFA) is a secondary metabolite biosynthetically related to ferulic acid in which a geranyl chain is attached to the phenolic group, extracted in 1966 from Acronychia baueri Schott (Fam. Rutaceae). In the last decade the pharmacological properties of the title compound began to be characterized, revealing its good activity as anti-inflammatory and dietary feeding cancer chemopreventive agent. The aim of this review is to examine in detail the recently reported properties of 4'-geranyloxyferulic acid from a chemical and pharmacological point of view, including the recent acquisition about its mechanism of action.

Keywords: 4'-geranyloxyferulic acid; Anti-cancer activity; GOFA; anti-inflammatory; anti-inflammatory activity; cancer chemoprevention; geranyl chain; neuroprotective effects; prenyloxycinnamic acids; rutaceae

Document Type: Research Article

Publication date: 01 July 2012

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content